Inhibition of XPO1 enhances cell death induced by ABT-199 in acute myeloid leukaemia via Mcl-1

Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study

(2018) Courtney D DiNardo et al.   LANCET ONCOLOGY

Binding of Released Bim to Mcl-1 is a Mechanism of Intrinsic Resistance to ABT-199 which can be Overcome by Combination with Daunorubicin or Cytarabine in AML Cells

(2016) X. Niu et al.   CLINICAL CANCER RESEARCH

BCL2 Inhibition by Venetoclax: Targeting the Achilles' Heel of the Acute Myeloid Leukemia Stem Cell?

(2016) V. A. Pullarkat et al.   Cancer Discovery

Efficacy and Biological Correlates of Response in a Phase II Study of Venetoclax Monotherapy in Patients with Acute Myelogenous Leukemia

(2016) M. Konopleva et al.   Cancer Discovery

Activity of a selective inhibitor of nuclear export, selinexor (KPT-330), against AML-initiating cells engrafted into immunosuppressed NSG mice

(2015) J Etchin et al.   LEUKEMIA

Expression, function, and targeting of the nuclear exporter chromosome region maintenance 1 (CRM1) protein

(2015) Jo Ishizawa et al.   PHARMACOLOGY & THERAPEUTICS

CHK1 plays a critical role in the anti-leukemic activity of the wee1 inhibitor MK-1775 in acute myeloid leukemia cells

(2014) Wenxiu Qi et al.   Journal of Hematology & Oncology

BCL-2 family proteins as 5-Azacytidine-sensitizing targets and determinants of response in myeloid malignancies

(2014) J M Bogenberger et al.   LEUKEMIA

Acute myeloid leukemia cells harboring MLL fusion genes or with the acute promyelocytic leukemia phenotype are sensitive to the Bcl-2-selective inhibitor ABT-199

(2014) X Niu et al.   LEUKEMIA

Clinical translation of nuclear export inhibitors in cancer

(2014) William T. Senapedis et al.   SEMINARS IN CANCER BIOLOGY

Mcl-1 Ubiquitination: Unique Regulation of an Essential Survival Protein

(2014) Barbara Mojsa et al.   Cells

Prognostic impact and targeting of CRM1 in acute myeloid leukemia

(2013) K. Kojima et al.   BLOOD

ABT-199, a new Bcl-2-specific BH3 mimetic, has in vivo efficacy against aggressive Myc-driven mouse lymphomas without provoking thrombocytopenia

(2013) C. J. Vandenberg et al.   BLOOD

Preclinical and clinical efficacy of XPO1/CRM1 inhibition by the karyopherin inhibitor KPT-330 in Ph+ leukemias

(2013) C. J. Walker et al.   BLOOD

ABT-199 selectively inhibits BCL2 but not BCL2L1 and efficiently induces apoptosis of chronic lymphocytic leukaemic cells but not platelets

(2013) Meike Vogler et al.   BRITISH JOURNAL OF HAEMATOLOGY

Targeting BCL-2 with the BH3 Mimetic ABT-199 in Estrogen Receptor-Positive Breast Cancer

(2013) François Vaillant et al.   CANCER CELL

The Bcl-2 specific BH3 mimetic ABT-199: a promising targeted therapy for t(11;14) multiple myeloma

(2013) C Touzeau et al.   LEUKEMIA

ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets

(2013) Andrew J Souers et al.   NATURE MEDICINE

Panobinostat Enhances Cytarabine and Daunorubicin Sensitivities in AML Cells through Suppressing the Expression of BRCA1, CHK1, and Rad51

(2013) Chengzhi Xie et al.   PLoS One

Selective BCL-2 Inhibition by ABT-199 Causes On-Target Cell Death in Acute Myeloid Leukemia

(2013) R. Pan et al.   Cancer Discovery

Selective inhibitors of nuclear export show that CRM1/XPO1 is a target in chronic lymphocytic leukemia

(2012) R. Lapalombella et al.   BLOOD

Targeting the B-Cell Lymphoma/Leukemia 2 Family in Cancer

(2012) Matthew S. Davids et al.   JOURNAL OF CLINICAL ONCOLOGY

Nuclear export of proteins and drug resistance in cancer

(2011) Joel G. Turner et al.   BIOCHEMICAL PHARMACOLOGY

The vascular niche: home for normal and malignant hematopoietic stem cells

(2011) P L Doan et al.   LEUKEMIA

Inhibition of Histone Deacetylases 1 and 6 Enhances Cytarabine-Induced Apoptosis in Pediatric Acute Myeloid Leukemia Cells

(2011) Xuelian Xu et al.   PLoS One

Mechanisms of Synergistic Antileukemic Interactions between Valproic Acid and Cytarabine in Pediatric Acute Myeloid Leukemia

(2010) C. Xie et al.   CLINICAL CANCER RESEARCH

Mcl-1; the molecular regulation of protein function

(2010) Luke W. Thomas et al.   FEBS LETTERS

RUNX1 regulates phosphoinositide 3-kinase/AKT pathway: role in chemotherapy sensitivity in acute megakaryocytic leukemia

(2009) H. Edwards et al.   BLOOD

Identification of Nuclear Export Inhibitors with Potent Anticancer Activity In vivo

(2009) S. C. Mutka et al.   CANCER RESEARCH

EXPRESSION OF CRM1 IN HUMAN GLIOMAS AND ITS SIGNIFICANCE IN P27 EXPRESSION AND CLINICAL PROGNOSIS

(2009) Aiguo Shen et al.   NEUROSURGERY

A Phase I Study of the Pan Bcl-2 Family Inhibitor Obatoclax Mesylate in Patients with Advanced Hematologic Malignancies

(2008) A. D. Schimmer et al.   CLINICAL CANCER RESEARCH

An Essential Role for MCL-1 in ATR-mediated CHK1 Phosphorylation

(2008) Sarwat Jamil et al.   MOLECULAR BIOLOGY OF THE CELL

The BCL-2 protein family: opposing activities that mediate cell death

(2007) Richard J. Youle et al.   NATURE REVIEWS MOLECULAR CELL BIOLOGY